Lipid nanoparticles technology in vaccines: Shaping the future of prophylactic medicine.

Ahmed A H Abdellatif, Mahmoud A Younis, Abdullah F Alsowinea, Emad M Abdallah, Mohamed S Abdel-Bakky, Amal Al-Subaiyel, Yasser A H Hassan, Hesham M Tawfeek

Colloids and surfaces. B, Biointerfaces 2023 Feb

filter terms:

Throughout decades, the intrinsic power of the immune system to fight pathogens has inspired researchers to develop techniques that enable the prevention or treatment of infections via boosting the immune response against the target pathogens, which has led to the evolution of vaccines. The recruitment of Lipid nanoparticles (LNPs) as either vaccine delivery platforms or immunogenic modalities has witnessed a breakthrough recently, which has been crowned with the development of effective LNPs-based vaccines against COVID-19. In the current article, we discuss some principles of such a technology, with a special focus on the technical aspects from a translational perspective. Representative examples of LNPs-based vaccines against cancer, COVID-19, as well as other infectious diseases, autoimmune diseases, and allergies are highlighted, considering the challenges and promises. Lastly, the key features that can improve the clinical translation of this area of endeavor are inspired. Copyright © 2022 Elsevier B.V. All rights reserved.

Citation

Ahmed A H Abdellatif, Mahmoud A Younis, Abdullah F Alsowinea, Emad M Abdallah, Mohamed S Abdel-Bakky, Amal Al-Subaiyel, Yasser A H Hassan, Hesham M Tawfeek. Lipid nanoparticles technology in vaccines: Shaping the future of prophylactic medicine. Colloids and surfaces. B, Biointerfaces. 2023 Feb;222:113111